anti-CD16/anti-BCMA bispecific immune-cell engager (Oncopeptides)

N/A

Report date: 2025/03/20 09:19:47

Base Information

Drug Nameanti-CD16/anti-BCMA bispecific immune-cell engager (Oncopeptides)
Drug Alias NameNK cell enganging synthetic polypeptide (Oncopeptides)anti-CD16/anti-BCMA bispecific NK-cell engager (Oncopeptides AB)
ClassificationBiologics > Protein drugs > Recombinant polypeptideBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsLow affinity immunoglobulin gamma Fc region receptor III agonists
TargetsLow affinity immunoglobulin gamma Fc region receptor IIITumor necrosis factor ligand superfamily member 13
Therapy Area/IndicationsHematologic NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOncopeptides Ab
China Registration ClassN/A

Develop Information

Active CompaniesOncopeptides Ab
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A